ASX Release No. 1043 26 February 2020 Page 1 of 1 ACN 090 987 250 ASX Release Investor Presentation PERTH, AUSTRALIA – 26 February 2020: SUDA Pharmaceuticals Ltd (ASX: SUD), a leader in oro-mucosal drug delivery, is pleased to announce that Dr Michael Baker and Mr David Phillips are attending the Wholesale Investor Emergence 2020 conference in Sydney from 26 – 28 February 2020. Dr Baker will be presenting on Thursday 27 February. A copy of the Investor Presentation follows. For and on behalf of the Board and for further information please contact: Paul Hopper Dr Michael Baker Executive Chairman Chief Executive Officer SUDA Pharmaceuticals Ltd SUDA Pharmaceuticals Ltd Tel: +61 (0) 406 671 515 Tel +61 (0) 403 468 187 [email protected][email protected]NOTES TO EDITORS: About SUDA Pharmaceuticals Ltd SUDA Pharmaceuticals Ltd (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia. The Company is developing low-risk oral sprays using its OroMist® technology to reformulate existing pharmaceuticals. The many potential benefits of administering drugs through the oral mucosa (i.e.: cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. SUDA’s product pipeline includes ZolpiMist™, a first-in-class oral spray of zolpidem for insomnia. ZolpiMist is marketed in the USA and SUDA has rights to the product outside of the US and Canada. Other products in development include oral sprays for the treatment of: migraine headache; chemotherapy-induced nausea and vomiting; erectile dysfunction; pulmonary hypertension; epileptic seizures and pre-procedural anxiety and cancer. For more information, visit www.sudapharma.com
Transcript
ASX Release No. 1043 26 February 2020 Page 1 of 1
ACN 090 987 250
ASX Release
Investor Presentation
PERTH, AUSTRALIA – 26 February 2020: SUDA Pharmaceuticals Ltd (ASX: SUD), a leader in oro-mucosal drug delivery, is pleased to announce that Dr Michael Baker and Mr David Phillips are attending the Wholesale Investor Emergence 2020 conference in Sydney from 26 – 28 February 2020.
Dr Baker will be presenting on Thursday 27 February.
A copy of the Investor Presentation follows.
For and on behalf of the Board and for further information please contact:
SUDA Pharmaceuticals Ltd (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia. The Company is developing low-risk oral sprays using its OroMist® technology to reformulate existing pharmaceuticals. The many potential benefits of administering drugs through the oral mucosa (i.e.: cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. SUDA’s product pipeline includes ZolpiMist™, a first-in-class oral spray of zolpidem for insomnia. ZolpiMist is marketed in the USA and SUDA has rights to the product outside of the US and Canada. Other products in development include oral sprays for the treatment of: migraine headache; chemotherapy-induced nausea and vomiting; erectile dysfunction; pulmonary hypertension; epileptic seizures and pre-procedural anxiety and cancer.
▪ Potentially smaller doses & safer delivery for ex-blockbuster drugs.
▪ Dosing in difficult populations – Seizures, inability to swallow, paediatrics.
▪ Large target markets: Including insomnia ($4b by 2026), migraine ($9b by 2026), medical grade cannabis ($66b by 2025) and cancer ($424b for solid tumours by 2027).
▪ Faster path to market: We can leverage a drug’s prior safety and efficacy data which can save time and development costs.
▪ Validation of the Technology: Deals with Teva, Mitsubishi, Strides, Zelira Therapeutics, Cann Pharma, Laboratorios Ordesa and Sanofi.
▪ Anagrelide: Approved generic drug to treat a rare blood disorder where a patient’s platelet count is too high.
▪ Recent Research Shows: Cancer patients with high platelet counts have a poor prognosis, lowering the platelet count could play an important role in cancer treatment.
▪ Making Anagrelide Safer: As a pill, it has cardiac side effects, SUDAs oro-mucosal spray may limit unwanted side effects.
▪ Reformulation work: Conversion into an OroMist spray is ongoing.
▪ SUDA owns intellectual property:
▪ “Prevention and treatment of metastatic disease in thrombocytotic cancer patients”
▪ We have the team: Dr Richard Franklin is the Project Director, involved in progressing Agrylin® through to approval throughout Europe.
▪ Anagrelide may be broadly applicable: Broad spectrum of solid tumors demonstrate a common dependency on high platelet count.
David was a senior audit partner with Ernst & Young from 1989 to 2017. From 2008 to 2013, David led the Capital Markets desk in Australia with responsibility for
overseeing or reviewing all Australian cross border
fundraisings. David is currently a member of the Board of MS
